List view / Grid view
23 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The two studies, FLAIR and ATLAS, will examine the safety and efficacy of monthly dosing with the two-drug, injectable regimen in both treatment-naïve...
16 August 2016 | By ViiV Healthcare
ViiV Healthcare is undertaking two identical studies as part of a global phase III programme comparing a two-drug regimen of dolutegravir plus lamivudine, with a three-drug regimen of dolutegravir (Tivicay), plus the fixed-dose tablet tenofovir/emtricitabine (Truvada), to support regulatory filings as a treatment for HIV, for adults who have had…
19 July 2016 | By Victoria White, Digital Content Producer
Triumeq demonstrated superior efficacy compared with ATV/r plus TDF/FTC in 495 treatment-naïve women living with HIV...
28 April 2016 | By Jon Pender, VP Government Affairs, GSK
Jon Pender, GSK, discusses how a flexible and thoughtful approach to IP can help get medicines to the poorest and hardest-to-reach patients around the world...
8 January 2016 | By Victoria White
ViiV Healthcare has formalised its collaboration with Janssen for the Phase III investigation and commercialisation of the injectable formulations of cabotegravir and rilpivirine...
18 December 2015 | By Victoria White
ViiV will pay to Bristol-Myers Squibb upfront payments totaling $350 million with potential development and regulatory milestone payments of up to $518 million for the clinical assets and up to $587 million for the discovery and preclinical programmes...
3 November 2015 | By Victoria White
Results from the study show that cabotegravir and rilpivirine were comparable in maintaining viral suppression rates to a three drug oral regimen...
23 September 2015 | By Victoria White
A Phase IIIb/IV study demonstrated that viral suppression was non-inferior for patients switching to once-daily Triumeq from an antiretroviral therapy...
3 July 2015 | By Victoria White
ViiV Healthcare and Desano Pharmaceuticals have announced a strategic manufacturing agreement to enable production of dolutegravir in China...
27 November 2014 | By ViiV Healthcare
Landmark number of grants awarded for 2015 as the Positive Action for Children Fund hits 5 year milestone...
5 September 2014 | By GlaxoSmithKline
ViiV Healthcare announced that the European Commission has granted marketing authorisation for Triumeq® (dolutegravir 50mg / abacavir 600mg / lamivudine 300mg) tablets...
26 August 2014 | By GlaxoSmithKline
ViiV Healthcare announced that the US Food and Drug Administration has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection...
22 July 2014 | By GlaxoSmithKline
...with emtricitabine/tenofovir plus darunavir/ritonavir in treatment-naïve adults with HIV-1.
12 June 2014 | By GlaxoSmithKline
Agreement is ViiV Healthcare’s first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine...
ViiV Healthcare is pleased to announce that the U.S. FDA has approved Tivicay® (dolutegravir) 50-mg tablets...
